PAC Synthesis
Financiado
Synthesis of PROTAC Antibody Conjugate for Application in Acute Myeloid Leukemia...
The field of immunotherapy has become one of the most promising strategies in fighting cancer. By using the incredible features our very own immune system already possesses, like the powerful tool of specific antibody-antigen reco...
The field of immunotherapy has become one of the most promising strategies in fighting cancer. By using the incredible features our very own immune system already possesses, like the powerful tool of specific antibody-antigen recognition, a new generation of drugs can be generated. The idea of linking cytotoxic drugs to monoclonal antibodies with high affinities to specific tumor cells will tremendously improve drug delivery, as tumor-associated antigens can be found by antibodies and the high cytotoxicity of the conjugated drug is used to achieve efficient cancer treatment with less side effects. In this research proposal, we establish a new therapeutic platform that uniquely combines the advantages of two rapidly developing areas – immunotherapy and targeted protein degradation – by developing first class of PROTAC-Antibody Conjugates (PAC). The resulting novel therapeutic agents will help to overcome the limitations arising from lack of cell specificity of PROTACs by exploiting tissue-specificity of the antibody component. Several studies reported encouraging data for the treatment of acute myeloid leukemia (AML) with antibody drug conjugates (ADC) that target the myeloid antigen CD33. In addition, a functionalisable BET inhibitor will be employed in protein degrader construct, generating a new class of small-molecule BET protein degraders. Besides, the proposed self-immolative linker chemistry will allow the traceless realease of the PROTAC once the PAC is internalized into the target cell. Moreover, we will use novel site-selective cysteine bioconjugation approach to build homogenous conjugates that, unlike current examples built using maleimide chemistry, are fully stable in the blood. Overall, this approach will be applicable to any protein of interest and therefore has the potential to advance not only the AML treatment but also the whole field of cancer therapy.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2020-03-26
Fecha Fin: 2022-04-30
Fecha Fin: 2022-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2019:
Individual Fellowships
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
213K€
Líder del proyecto
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
180.94K€ |
Participante